Free tool
Drug Trial Radar: Hematology and blood cancers
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
1,472
Completed, industry sponsors, Hematology and blood cancers, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting411
- Completed1,472
1,472 trials
Showing 1 to 25, recently updated first.
AbbVieAbbVie (ABBV)
NCT03386513 · 179 participants · Start Jan 2, 2018 · Primary completion Oct 2, 2024
Drug: IMGN632 · For: Blastic Plasmacytoid Dendritic Cell Neoplasm; Myeloproliferative Neoplasm
Sites: Birmingham, Alabama; Gilbert, Arizona; Duarte, California · 18 sites in all
- CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)Completed
Vittoria BiotherapeuticsIndustry
NCT06420089 · 19 participants · Start Oct 4, 2024 · Primary completion Sep 24, 2026
Drug: Senza5 CART5 · For: T Cell Non-Hodgkin Lymphoma
Sites: New York, New York; Philadelphia, Pennsylvania
Hope Biosciences LLCIndustry
NCT04063215 · 24 participants · Start Jan 1, 2020 · Primary completion Oct 25, 2024
Drug: HB-adMSCs · For: Traumatic Brain Injury
Sites: Houston, Texas
CRISPR TherapeuticsIndustry
NCT06492304 · 12 participants · Start Aug 13, 2024 · Primary completion Mar 11, 2026
Drug: CTX131 · For: T Cell Lymphoma; B Cell Lymphoma; Acute Myeloid Leukemia
Sites: Phoenix, Arizona; Stanford, California; Boston, Massachusetts · 7 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06618001 · 64 participants · Start Jan 14, 2025 · Primary completion Sep 1, 2026
Drug: JNJ-89853413 · For: Leukemia, Myeloid, Acute; Myelodysplastic Neoplasms
Sites: Calgary, Canada; Vancouver, Canada; Toronto, Canada · 9 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03533283 · 211 participants · Start May 8, 2018 · Primary completion Oct 22, 2026
Drug: Glofitamab; Atezolizumab and 4 more · For: Non-Hodgkins Lymphoma
Sites: Charlotte, North Carolina; Ghent, Belgium; Aarhus N, Denmark · 20 sites in all
Chongqing Peg-Bio Biopharm Co., Ltd.Industry
NCT07446491 · 54 participants · Start Jun 6, 2025 · Primary completion Oct 10, 2026
Drug: PN20; Placebo · For: Thrombocytopenia Associated With Chronic Liver Disease
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 8 sites in all
Chongqing Peg-Bio Biopharm Co., Ltd.Industry
NCT06880081 · 12 participants · Start Mar 7, 2025 · Primary completion Feb 14, 2026
Drug: PN20 treatment · For: Primary Immune Thrombocytopenia (ITP)
Sites: Guiyang, China; Nanchang, China; Jining, China · 5 sites in all
Evopoint Biosciences Inc.Industry
NCT06558513 · 120 participants · Start Aug 3, 2021 · Primary completion Aug 30, 2025
Drug: XNW5004 tablets · For: Advanced Tumor; Lymphoma
Sites: Tianjin, China
Werewolf Therapeutics, Inc.Industry
NCT06939283 · 24 participants · Start Apr 21, 2025 · Primary completion Apr 23, 2026
Drug: WTX-330 · For: Advanced or Metastatic Solid Tumors; Non-Hodgkin Lymphoma
Sites: Scottsdale, Arizona; Atlanta, Georgia; Chicago, Illinois · 5 sites in all
- Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint InhibitorsCompleted
Cytosite Biopharma Inc.Industry
NCT04169321 · 13 participants · Start Jun 16, 2020 · Primary completion Mar 30, 2025
Drug: Single Arm · For: Solid Tumor, Unspecified, Adult; Lymphoma
Sites: Birmingham, Alabama; Boston, Massachusetts; Taoyuan City, Taiwan
Eli Lilly and CompanyEli Lilly (LLY)
NCT05024045 · 27 participants · Start Sep 30, 2021 · Primary completion Jun 14, 2023
Drug: LOXO-338; Pirtobrutinib · For: Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-cell Marginal Zone; Lymphoma, Non-Hodgkin and 4 more
Sites: Tucson, Arizona; Duarte, California; San Francisco, California · 23 sites in all
Incyte CorporationIncyte (INCY)
NCT04455841 · 84 participants · Start Mar 19, 2021 · Primary completion Apr 1, 2025
Drug: INCB000928; ruxolitinib · For: Anemia; Post-essential Thrombocythemia Myelofibrosis; Post-polycythemia Vera Myelofibrosis
Sites: Duarte, California; Irvine, California; Los Angeles, California · 34 sites in all
Sumitomo Pharma America, Inc.Industry
NCT07444268 · 8 participants · Start Mar 26, 2026 · Primary completion Aug 11, 2026
Drug: DSP-5336; [14C]-DSP-5336 · For: Advanced Hematologic Malignancies
Sites: Chapel Hill, North Carolina; Houston, Texas
- Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's LymphomasCompleted
Alaunos TherapeuticsIndustry
NCT00591422 · 23 participants · Start Aug 2007 · Primary completion Mar 10, 2010
Drug: ZIO-101-C (Darinaparsin) · For: Advanced Cancer
Sites: Ocoee, Florida; Dallas, Texas; Norfolk, Virginia
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06813924 · 37 participants · Start Feb 6, 2025 · Primary completion May 27, 2025
Drug: Etavopivat; Digoxin and 4 more · For: Healthy Volunteers Sickle Cell Disease, Thalassemia
Sites: Salt Lake City, Utah
Alaunos TherapeuticsIndustry
NCT00592163 · 20 participants (planned) · Start Dec 2007 · Primary completion Jan 4, 2009
Drug: ZIO-101-C (Darinaparsin) · For: Advanced Solid Tumors; Lymphomas
Sites: Montreal, Canada
Jasper Therapeutics, Inc.Industry
NCT04429191 · 32 participants · Start Jul 8, 2020 · Primary completion Jun 13, 2023
Drug: Humanized anti-CD117 Monoclonal Antibody (JSP191) · For: MYELODYSPLASTIC SYNDROME; MDS; ACUTE MYELOID LEUKEMIA; AML
Sites: Duarte, California; Stanford, California; Chicago, Illinois · 6 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07295951 · 6 participants · Start Nov 18, 2025 · Primary completion Jul 21, 2026
Drug: 14C-bleximenib; bleximenib · For: Acute Lymphoblastic Leukemia; Acute Leukemias; Acute Myeloid Leukemia
Sites: Manchester, United Kingdom
Molecular Partners AGIndustry
NCT05673057 · 80 participants · Start Dec 29, 2022 · Primary completion May 29, 2026
Drug: MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1; MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 2-Arm A and 4 more · For: Leukemia; Myeloid; Acute and 1 more
Sites: Bordeaux, France; Paris, France; Toulouse, France · 9 sites in all
ImmuneOncia Therapeutics Inc.Industry
NCT04306224 · 12 participants · Start Jun 5, 2020 · Primary completion Oct 7, 2022
Drug: IMC-002 · For: Solid Tumor; Lymphoma
Sites: St Louis, Missouri; Houston, Texas; San Antonio, Texas · 4 sites in all
BayerBayer (BAYRY)
NCT03588299 · 11 participants · Start Nov 7, 2018 · Primary completion Sep 15, 2026
Drug: BAY2599023 (DTX201) · For: Hemophilia A
Sites: Little Rock, Arkansas; Ann Arbor, Michigan; Madison, Wisconsin · 13 sites in all
Biomea Fusion Inc.Industry
NCT05918692 · 35 participants · Start Jul 26, 2023 · Primary completion Jan 1, 2026
Drug: BMF-500 · For: Acute Myeloid Leukemia
Sites: Phoenix, Arizona; Duarte, California; San Francisco, California · 14 sites in all
Eucure (Beijing) Biopharma Co., LtdIndustry
NCT05040932 · 8 participants · Start Dec 7, 2021 · Primary completion Jun 16, 2023
Drug: YH004 · For: Cancer
Sites: Wollongong, Australia; Malvern East, Australia; Sydney, Australia
Eucure (Beijing) Biopharma Co., LtdIndustry
NCT05564806 · 9 participants · Start Jan 31, 2023 · Primary completion Mar 11, 2024
Drug: YH004 · For: Advanced Solid Tumors; Relapsed Or Refractory Non-Hodgkin Lymphoma
Sites: Zhengzhou, China; Hangzhou, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.